AGIO — Agios Pharmaceuticals, Inc. stock price, charts and financials

Latest market price

32.20

-0.07-0.23%

Overview Short InterestFilings

AGIOQT53Agios Pharmaceuticals, Inc.·NASDAQ

Overview Short InterestFilings

32.20-0.23%

Loading chart...

Signal & projected range

Insider open-market saleHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

AUPH-2.40%$15.47 MESO+4.89%$16.72 ZBIO-1.46%$31.96 GHRS-1.65%$29.77 TSHA-1.45%$6.46 STOK-1.65%$32.17 ABCL+36.44%$9.46 VRDN-3.25%$22.82

Snapshot

Index	-	P/E	-	EPS (ttm)	-7.01	Insider Own	1.74%	Shs Outstand	59.70M	Perf Week	7.50%

Market Cap	1.93B	Forward P/E	-	EPS next Y	-4.02	Insider Trans	-11.07%	Shs Float	55.89M	Perf Month	-24.59%

Enterprise Value	1.86B	PEG	0.03	EPS next Q	-1.28	Inst Own	-	Short Float	11.86%	Perf Quarter	17.22%

Income	-412.67M	P/S	19.59	EPS this Y	16.45%	Inst Trans	-	Short Ratio	5.79	Perf Half Y	21.45%

Sales	98.34M	P/B	1.87	EPS next Y	31.37%	ROA	-37.11%	Short Interest	6.63M	Perf YTD	18.55%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-35.67%	52W High	45.90 -29.85%	Perf Year	-14.45%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-43.30%	52W Low	22.19 45.10%	Perf 3Y	24.21%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	56.83% -	Gross Margin	87.92%	Volatility	4.10% 5.12%	Perf 5Y	-32.90%

Dividend TTM	-	EV/Sales	18.90	EPS Y/Y TTM	-160.22%	Oper. Margin	-466.78%	ATR (14)	1.91	Perf 10Y	-26.42%

Dividend Ex-Date	-	Quick Ratio	9.79	Sales Y/Y TTM	175.00%	Profit Margin	-418.24%	RSI (14)	39.87	Recom	2.24

Dividend Gr. 3/5Y	-	Current Ratio	10.22	EPS Q/Q	12.44%	SMA20	-9.56%	Beta	0.59	Target Price	42.67

Payout	0.00%	Debt/Eq	0.03	Sales Q/Q	275.00%	SMA50	-6.48%	Rel Volume	1.07	Prev Close	32.27

Employees	540	LT Debt/Eq	0.02	Earnings	Oct 29	SMA200	2.85%	Avg Volume	1.10M	Price	32.20

IPO Date	Jul 24, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	-2.13% 69.52%	Net Debt/EBITDA	0.16	Volume	1,178,867	Change	-0.23%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-30-26	Reiterated	HC Wainwright & Co.	Buy	$52 → $55
Jul-21-26	Reiterated	HC Wainwright & Co.	Buy	$54 → $52
Jul-07-26	Reiterated	RBC Capital	Sector Perform	$53 → $32
Jul-07-26	Reiterated	Truist Securities	Buy	$36 → $41
Jun-15-26	Reiterated	HC Wainwright & Co.	Buy	$50 → $54
Apr-30-26	Reiterated	Truist Securities	Buy	$39 → $36
Apr-20-26	Reiterated	HC Wainwright & Co.	Buy	$62 → $50
Feb-12-26	Reiterated	Truist Financial	Buy	$38 → $39
Dec-26-25	Reiterated	Leerink Partners	Outperform	$34 → $40
Dec-24-25	Reiterated	HC Wainwright & Co.	Buy	$56 → $62

Latest News

Aug-07-26

Aug-07-2611:36AM

JP Morgan Maintains Neutral on Agios Pharmaceuticals, Raises Price Target to $34Benzinga

Aug-04-26

Aug-04-2605:07PM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIOglobenewswire.com

Aug-03-26

Aug-03-2604:16AM

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given Consensus Recommendation of “Hold” by Brokeragesdefenseworld.net

Jul-31-26

Jul-31-2603:36PM

Citigroup Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $52Benzinga

01:21PM

AGIO Q2 Earnings Beat Estimates, Revenues Increase Year Over Yearzacks.com

Jul-30-26

Jul-30-2603:34PM

HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $55Benzinga

01:53PM

Agios Pharmaceuticals, Inc. (AGIO) Q2 2026 Earnings Call Transcriptseekingalpha.com

10:06AM

Agios Pharmaceuticals Q2 Earnings Call Highlightsmarketbeat.com

08:51AM

Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimateszacks.com

06:30AM

Agios Reports Second Quarter 2026 Financial Results and Provides Business Updateglobenewswire.com

Jul-28-26

Jul-28-2605:24PM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIOglobenewswire.com

Jul-27-26

Jul-27-2601:41PM

Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?zacks.com

Jul-23-26

Jul-23-2611:01AM

Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Releasezacks.com

Jul-22-26

Jul-22-2601:26PM

AGIO Shares Sink Nearly 7% After Scrapping the Tebapivat SCD Programzacks.com

Jul-21-26

Jul-21-2601:35PM

10 Health Care Stocks With Whale Alerts In Today’s SessionBenzinga

Company

Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	99	54	36	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	12	12	4	—	—	—	—	—	—
Gross Profit	87	43	32	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	193	180	157	—	—	—	—	—	—
Research and Development	353	334	301	—	—	—	—	—	—
Other Operating Expense	-1	1	0	—	—	—	—	—	—
Operating Income	-460	-472	-426	—	—	—	—	—	—
Interest Expense	0	0	0	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	47	58	1,144	—	—	—	—	—	—
Net Income Before Taxes	-412	-414	718	—	—	—	—	—	—
Income Taxes	-1	-1	44	—	—	—	—	—	—
Consolidated Net Income	-411	-413	674	—	—	—	—	—	—
Net Income From Continuing Operations	-411	-413	674	—	—	—	—	—	—
Net Income	-411	-413	674	—	—	—	—	—	—
EPS (Recurring)	-7.01	-7.12	11.86	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-7.01	-7.12	11.86	—	—	—	—	—	—
EPS (Diluted)	-7.01	-7.12	11.64	—	—	—	—	—	—
EBITDA	-417	-409	724	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	2.82	—	—	—	—	—	—
Price To Sales Ratio	19.19	29.24	52.03	—	—	—	—	—	—
Gross Margin	87.88	79.63	88.89	—	—	—	—	—	—
Operating Margin	-464.65	-874.07	-1,183.33	—	—	—	—	—	—
Net Margin	-415.15	-764.81	1,872.22	—	—	—	—	—	—
Shares Outstanding	59	58	57	—	—	—	—	—	—
Market Capitalization	1,900	1,579	1,873	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gheuens Sarah	Chief Medical Officer	Aug 04 '26	Sale	30.48	30,000	914,400	54,645	Aug 06
Backstrom Jay T.	Director	Jul 08 '26	Option Exercise	0.00	1,447	0	2,894	Jul 10
Gheuens Sarah	Chief Medical Officer	Jul 01 '26	Option Exercise	0.00	8,375	0	88,652	Jul 02
Gheuens Sarah	Chief Medical Officer	Jul 01 '26	Sale	37.56	4,007	150,503	84,645	Jul 02
Ballal Rahul D.	Director	Jun 18 '26	Option Exercise	0.00	2,816	0	15,230	Jun 23
CAPELLO JEFFREY D	Director	Jun 18 '26	Option Exercise	0.00	2,816	0	10,865	Jun 23
Foster-Cheek Kaye I	Director	Jun 18 '26	Option Exercise	0.00	2,816	0	10,284	Jun 23
FOUSE JACQUALYN A	Director	Jun 18 '26	Option Exercise	0.00	2,816	0	154,156	Jun 23
Ho Maykin	Director	Jun 18 '26	Option Exercise	0.00	2,816	0	19,848	Jun 23
Owen Adams Catherine	Director	Jun 18 '26	Option Exercise	0.00	2,816	0	10,865	Jun 23
Scadden David	Director	Jun 18 '26	Option Exercise	0.00	2,816	0	20,419	Jun 23
Smith Cynthia	Director	Jun 18 '26	Option Exercise	0.00	2,816	0	15,230	Jun 23
Viswanadhan Krishnan	Chief Strategy and Operations	Jun 18 '26	Option Exercise	0.00	3,000	0	9,000	Jun 23
Goff Brian	Chief Executive Officer	Jun 18 '26	Option Exercise	0.00	39,000	0	39,000	Jun 23
Burns James William	Chief Legal Officer	Jun 18 '26	Option Exercise	0.00	3,000	0	9,000	Jun 23

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.